Page 23 - Anjali Singh

Indian commercial vehicle industry to see 3-5% growth in FY26: Icra

ICRA projects modest 3-5 per cent growth for CV sector in FY26 on infrastructure revival, with buses outpacing other segments at 8-10 per cent growth

Indian pharma eyes US gains as $63.7 bn patent cliff nears: Analysts

Shift is expected to drive a sharp increase in generic drug launches, positioning Indian drugmakers for strong growth

The times, they are a-changing: Anand Mahindra flags geopolitical flux

Mahindra likens global flux to Samudra Manthan and urges Indian industry to embrace innovation, invest in manufacturing, and act swiftly to capture supply chain realignment

Genomic testing sees sharp uptake in India, now growing beyond metros

With 18 per cent CAGR, India's genomic diagnostics market is expanding into Tier 2 and 3 cities as affordability, cancer screening, and personalised care fuel adoption

Sun Pharma partner Philogen withdraws EU application for skin cancer drug

Experts believe that the drug still holds potential for future market entry, and the current development should be viewed as a temporary setback

Bharat Biotech, GSK to cut malaria vaccine price by half for children

Aiming for global equity, Bharat Biotech and GSK will reduce the RTS,S vaccine price by over 50 per cent by 2028 through expanded production and tech transfer

Novo Nordisk launches Wegovy in India to rival Eli Lilly's weight-loss drug

Wegovy enters the Indian market as the first GLP-1 drug approved for both weight loss and cardiovascular risk reduction, competing with Eli Lilly's Mounjaro

Kashmik Formulation targets ₹100 crore revenue in FY26, eyes IPO

The company currently produces around 25 crore units a month and is expanding its ground and first-floor production facilities to meet rising demand

One in three young adults in Delhi shows signs of early lung damage

Mahajan Labs data from over 4,000 CT scans in 2024 reveals high incidence of early-stage lung abnormalities in Delhi youth, likely tied to pollution and lifestyle

Entry-level bikes vroom ahead on rural sentiment, rate cut push

Sub-125cc segment is 29% of motorcycle sales, 18% of two-wheeler volumes

Inventories of rare earth magnets may run dry by mid-July, says Icra

ICRA warns that rare-earth magnet inventories for EV motors may run dry by mid-July as China tightens export rules, leaving Indian auto makers facing serious supply disruption

HDFC Bank-LKMM Trust row escalates amid claims over loan irregularities

As LKMM Trust questions the existence of a loan and cites missing documentation, HDFC Bank calls the allegations false and prepares for legal action to protect its interests

Hospitals raise cybersecurity spend amid rising attacks, AI adoption

As cyber threats grow more advanced, hospitals are raising cybersecurity budgets, adopting AI-driven tools and preparing for stricter healthcare data regulations

Auto sector faces slowdown due to rare earth magnet shortage: Crisil

Automakers may face production delays from July as rare earth magnet supply tightens following China's export curbs, with Crisil warning of disruptions in EV and hybrid output

TaMo eyes 40% CV, 16% PV market share; EV biz hits Ebitda breakeven

Tata Motors targets 40% share in CVs and 16% in PVs by FY27, plans major EV investments and demerger of vehicle businesses by end-2025

Two-wheeler sales may cross pre-Covid levels in FY26 on export rebound

CareEdge sees 8-9% growth in FY26 as domestic recovery, exports, EV adoption, and affordability drive two-wheeler demand beyond pre-Covid highs

HDFC Bank to pursue legal remedies against Mehta family of Lilavati Trust

The bank rejected the "malicious and baseless allegations" levelled against HDFC Bank's MD and CEO Sashidhar Jagdishan

Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda

The partnership marks a strategic boost to Dr Reddy's oncology portfolio and expands Alvotech's biosimilar pipeline as Keytruda patents near expiry

Classic Legends targets FY26 profitability with new launches, expansion

Classic Legends is betting big on product innovation, network expansion, and exports to achieve profit before tax (PBT)-level profitability by FY26, said a senior company executive

Zydus enters biologics CDMO market with $125 million acquisitions

Zydus Lifesciences will acquire two US biologics manufacturing facilities from Agenus for up to $125 million, gaining immediate manufacturing capabilities and expanding its global presence